Benefit of dapagliflozin is independent of LVEF

Affiliations

Comment

Gregory B Lim. Nat Rev Cardiol. 2020 Sep.

. 2020 Sep;17(9):540.

doi: 10.1038/s41569-020-0419-3.

No abstract available

Comment on

Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Bělohlávek J, Chopra VK, Dukát A, Kitakaze M, Merkely B, O'Meara E, Schou M, Vinh PN, McMurray JJV; DAPA-HF Investigators and Committees. Dewan P, et al. Eur J Heart Fail. 2020 Jul;22(7):1247-1258. doi: 10.1002/ejhf.1867. Epub 2020 Jun 15. Eur J Heart Fail. 2020. PMID: 32539224 Clinical Trial.

1. Dewan, P. et al. Efficacy and safety of sodium–glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.1867 (2020) - DOI - PubMed - PMC